blinatumomab

The treatment, called blinatumomab, is also in clinical development for the treatment of Non-Hodgkin lymphoma.

The Seattle Times 2012

The Company's lead program is a BiTE antibody known as blinatumomab, or MT103.

GEN News Highlights 2009

The Company's lead program is a BiTE antibody known as blinatumomab, or MT103.

unknown title 2009

The maker of antibodies and other biologics will manufacture the Bethesda-based biotech's drug, called blinatumomab, for clinical trials.

Dallas Business News - Local Dallas News | Dallas Business Journal 2009

The Company's lead program is a BiTE antibody known as blinatumomab, or MT103.

News 2009

Amgen highlighted Micromet's lead drug candidate, blinatumomab, an antibody being tested in clinical trials of people with acute lymphoblastic leukemia and non-Hodgkin's lymphoma.

Amgen to Buy Biotech Micromet for $1.16 Billion Peter Loftus 2012

Mr. Perlmutter said results of a small clinical trial of blinatumomab in leukemia, released in December, were promising.

Amgen to Buy Biotech Micromet for $1.16 Billion Peter Loftus 2012

The company said an early study of its antibody blinatumomab treatment for non-Hodgkin's lymphoma has shown high response rates in patients.

Headwaters Is Off, but Piedmont Is On 2009

Micromet launched a clinical development program to establish blinatumomab as a key component of treatment for adult and pediatric patients with early and advanced ALL.

unknown title 2011

These early validations were followed by a clinical validation from clinical trial results from Phase I trial of its drug blinatumomab on non-Hodgkin's lymphoma (NHL) and from Phase II clinical trial results on adult patients with acute lymphoblastic leukemia (ALL) who had relapsed following treatment with standard therapy.

unknown title 2011